,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,15883,3,3,,103178022,60021,Unspecified,,,,,Calculated partition coefficient (clogP),Other,8576916.0,
1,17991,3,3,,103178022,60021,Unspecified,,,,,Bioavailability,Other,12873497.0,
2,19478,3,5,,103178022,60021,Unspecified,,,,,Partition coefficient in octanol/water at pH 7.5 buffer.,Other,1846917.0,
3,20940,5,3,,103178022,60021,Unspecified,,,,,Compound was tested for its water solubility at pH 7.5,Other,1846917.0,
4,20941,5,2,,103178022,60021,Unspecified,,,,,Compound was tested for its water solubility in water.,Other,1846917.0,
5,30274,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Acinetobacter sp. CMX 669,Other,1846917.0,
6,54107,5,1,,103178022,60021,Unspecified,,,,,Minimum inhibitory concentration required to inhibit DNA gyrase supercoiling.,Other,2002456.0,
7,57388,7,4,,103178022,60021,Unspecified,,,,,Minimum inhibitory concentration against Escherichia coli DNA-gyrase in supercoiling assay,Other,1848296.0,
8,63898,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae MA2646",Other,1848296.0,
9,63899,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity against gram negative organism, Escherichia cloacae (MA2646)",Other,2002456.0,
10,64251,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Escherichia coli vogel",Other,1848296.0,
11,64254,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, E. coli(vogel)",Other,2002456.0,
12,67545,8,1,,103178022,60021,Unspecified,,,,,Activity against Enterobacter aerogenes,Other,12873497.0,
13,67866,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Enterobacter aerogenes ATCC 13048,Other,1846917.0,
14,68578,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Enterococcus faecium ATCC 8043,Other,1846917.0,
15,68830,6,2,,103178022,60021,Unspecified,,,,,Median dose against Escherichia coli Juhl in mouse after peroral administration at a dose of 100xLD50 in TEST 2.,Other,1846917.0,
16,68831,6,2,,103178022,60021,Unspecified,,,,,Median dose against Escherichia coli Juhl in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
17,68832,6,2,,103178022,60021,Unspecified,,,,,Median dose against Escherichia coli Juhl in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 2.,Other,1846917.0,
18,68964,6,2,,103178022,60021,Unspecified,,,,,Median dose against Escherichia coli Juhl cumulative mortalities in mouse after peroral administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
19,69602,6,2,,103178022,60021,Unspecified,,,,,Anti-bacterial activity was tested against Gram-negative EC-1 bacterium,Other,8576916.0,
20,69639,6,2,,103178022,60021,Unspecified,,,,,Minimum inhibitory concentration against Escherichia coli,Other,10737746.0,
21,70134,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli DC-2,Other,1846917.0,
22,70135,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli H-560,Other,1846917.0,
23,70136,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli Juhl,Other,1846917.0,
24,70137,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli KNK437,Other,1846917.0,
25,70138,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Escherichia coli SS,Other,1846917.0,
26,74723,4,3,,103178022,60021,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-negative bacteria,Other,1848296.0,
27,74734,4,3,,103178022,60021,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-positive bacteria,Other,1848296.0,
28,94001,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Klebsiella pneumoniae MGH-2",Other,1848296.0,
29,94063,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Klebsiella pneumoniae ATCC 8045,Other,1846917.0,
30,94123,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, K. pneumoniae (MGH-2)",Other,2002456.0,
31,123076,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Micrococcus luteus ATCC 4698,Other,1846917.0,
32,123077,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Micrococcus luteus ATCC 9341,Other,1846917.0,
33,144009,6,2,,103178022,60021,Unspecified,,,,,Anti-bacterial activity tested against Mycobacterium fortuitum (ATCG 6841),Other,8576916.0,
34,144438,6,2,,103178022,60021,Unspecified,,,,,Anti-bacterial activity tested against Mycobacterium smegmatis (ATCG 19420),Other,8576916.0,
35,150908,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa (UI-18)",Other,2002456.0,
36,151052,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa UI-18",Other,1848296.0,
37,151373,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Providencia rettgeri. (M1771)",Other,2002456.0,
38,151374,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram negative organism, Providencia rettgeri. M1771",Other,1848296.0,
39,163437,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa A5007,Other,1846917.0,
40,163438,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa BMH10,Other,1846917.0,
41,163439,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa K799/61,Other,1846917.0,
42,163440,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas aeruginosa K799/WT,Other,1846917.0,
43,163782,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Pseudomonas cepacia 2961,Other,1846917.0,
44,163892,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Providencia stuartii CMX 640,Other,1846917.0,
45,164215,6,2,,103178022,60021,Unspecified,,,,,Median dose against Pseudomonas aeruginosa A5007 in mouse after peroral administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
46,164216,6,2,,103178022,60021,Unspecified,,,,,Median dose against Pseudomonas aeruginosa A5007 in mouse after peroral administration at a dose of 100xLD50 in TEST 2.,Other,1846917.0,
47,164218,6,2,,103178022,60021,Unspecified,,,,,Median dose against Pseudomonas aeruginosa A5007 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
48,164219,6,2,,103178022,60021,Unspecified,,,,,Median dose against Pseudomonas aeruginosa A5007 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 2.,Other,1846917.0,
49,164235,6,2,,103178022,60021,Unspecified,,,,,Anti-bacterial activity tested against Gram-negative PA-7 bacterium,Other,8576916.0,
50,197877,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus H228",Other,1848296.0,
51,198020,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus faecalis (MGH-2)",Other,2002456.0,
52,198021,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus faecalis MGH-2",Other,1848296.0,
53,198174,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae (SV-1)",Other,2002456.0,
54,198176,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae SV-1",Other,1848296.0,
55,198316,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes (C203)",Other,2002456.0,
56,198317,7,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes C203",Other,1848296.0,
57,200230,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (H228)",Other,2002456.0,
58,200231,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (UC76)",Other,2002456.0,
59,200234,6,2,,103178022,60021,Unspecified,,,,,"Antibacterial activity was determined against gram positive organism, Staphylococcus aureus UC76",Other,1848296.0,
60,203263,6,2,,103178022,60021,Unspecified,,,,,Median dose against Staphylococcus aureus NCTC 10649 in mouse after peroral administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
61,203264,6,2,,103178022,60021,Unspecified,,,,,Median dose against Staphylococcus aureus NCTC 10649 in mouse after peroral administration at a dose of 100xLD50 in TEST 2.,Other,1846917.0,
62,203265,6,2,,103178022,60021,Unspecified,,,,,Median dose against Staphylococcus aureus NCTC 10649 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 2.,Other,1846917.0,
63,203266,6,2,,103178022,60021,Unspecified,,,,,Median dose against Staphylococcus aureus NCTC 10649 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
64,206047,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus epidermidis 3519,Other,1846917.0,
65,206492,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus 45,Other,1846917.0,
66,206493,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus 45 RAR2,Other,1846917.0,
67,206495,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus A5177,Other,1846917.0,
68,206496,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus ATCC 6538P,Other,1846917.0,
69,206497,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus CMX 553,Other,1846917.0,
70,206857,6,2,,103178022,60021,Unspecified,,,,,Anti-bacterial activity was tested against Gram-positive SA-13 bacterium,Other,8576916.0,
71,208755,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus agalactiae CMX 508,Other,1846917.0,
72,208921,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus bovis A5169,Other,1846917.0,
73,209122,6,2,,103178022,60021,Unspecified,,,,,Anti-bacterial activity tested against Gram-positive SP1-1 bacterium,Other,8576916.0,
74,209875,6,2,,103178022,60021,Unspecified,,,,,Median dose against Streptococcus pneumoniae 6303 in mouse after peroral administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
75,209876,6,2,,103178022,60021,Unspecified,,,,,Median dose against Streptococcus pneumoniae 6303 in mouse after subcutaneous administration at a dose of 100xLD50 in TEST 1.,Other,1846917.0,
76,209928,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus pyogenes 2548 INDUC,Other,1846917.0,
77,209929,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus pyogenes 930 Const,Other,1846917.0,
78,209930,6,2,,103178022,60021,Unspecified,,,,,The in vitro antibacterial activity as minimum inhibitory concentration against Streptococcus pyogenes EES61,Other,1846917.0,
79,230838,3,3,,103178022,60021,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-negative bacteria,Other,2002456.0,
80,230840,3,3,,103178022,60021,Unspecified,,,,,MIC ratio measured as the mean MICs of gram-positive bacteria,Other,2002456.0,
81,324745,6,4,,103178022,60021,Unspecified,,,,,Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling,Other,17325221.0,
82,324746,5,1,,103178022,60021,Unspecified,,,,,Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage,Other,17325221.0,
83,324747,3,5,,103178022,60021,Unspecified,,,,,Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days,Other,17325221.0,
84,324753,3,7,,103178022,60021,Unspecified,,,,,Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at 50 mg/kg/day after 9 months,Other,17325221.0,
85,588209,2,3,,103178022,60021,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
86,588210,2,4,,103178022,60021,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
87,602332,1,1,,124894572,60021,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
88,624030,1,2,,124894572,60021,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
89,624170,1,1,,124894572,60021,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
90,624172,1,1,,124894572,60021,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
91,624173,1,3,,124894572,60021,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
92,625144,5,5,,103178022,60021,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
93,625145,4,7,,103178022,60021,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
94,625146,5,5,,103178022,60021,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
95,625147,4,7,,103178022,60021,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
96,625148,4,7,,103178022,60021,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
97,625149,4,7,,103178022,60021,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
98,625150,5,5,,103178022,60021,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
99,625151,4,7,,103178022,60021,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
100,625152,4,7,,103178022,60021,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
101,625153,4,7,,103178022,60021,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
102,625154,4,7,,103178022,60021,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
103,625155,4,7,,103178022,60021,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
104,625156,1,9,,103178022,60021,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
105,625157,6,2,,103178022,60021,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
106,625158,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
107,625159,5,5,,103178022,60021,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
108,625160,1,9,,103178022,60021,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
109,625161,4,7,,103178022,60021,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
110,625162,4,7,,103178022,60021,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
111,625163,4,7,,103178022,60021,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
112,625164,1,6,,103178022,60021,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
113,625165,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
114,625166,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
115,625167,5,5,,103178022,60021,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
116,625168,4,7,,103178022,60021,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
117,625169,1,6,,103178022,60021,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
118,625170,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
119,625171,4,7,,103178022,60021,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
120,625172,4,7,,103178022,60021,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
121,625173,5,5,,103178022,60021,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
122,625174,5,5,,103178022,60021,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
123,625175,5,5,,103178022,60021,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
124,625176,1,9,,103178022,60021,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
125,625177,5,5,,103178022,60021,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
126,625178,5,5,,103178022,60021,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
127,625179,1,9,,103178022,60021,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
128,625180,5,5,,103178022,60021,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
129,625181,5,5,,103178022,60021,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
130,625182,5,5,,103178022,60021,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
131,625183,5,5,,103178022,60021,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
132,625184,5,5,,103178022,60021,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
133,625185,5,5,,103178022,60021,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
134,625186,5,5,,103178022,60021,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
135,625187,5,5,,103178022,60021,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
136,625188,1,9,,103178022,60021,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
137,625189,1,7,,103178022,60021,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
138,625190,4,5,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
139,625191,4,7,,103178022,60021,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
140,625192,4,7,,103178022,60021,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
141,625193,5,5,,103178022,60021,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
142,625194,4,7,,103178022,60021,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
143,625195,4,7,,103178022,60021,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
144,625196,5,6,,103178022,60021,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
145,625197,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
146,625198,4,7,,103178022,60021,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
147,625199,4,7,,103178022,60021,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
148,625200,4,7,,103178022,60021,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
149,625201,4,7,,103178022,60021,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
150,625202,4,7,,103178022,60021,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
151,625203,4,7,,103178022,60021,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
152,625204,4,7,,103178022,60021,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
153,625205,4,7,,103178022,60021,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
154,625206,4,7,,103178022,60021,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
155,625207,4,7,,103178022,60021,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
156,625208,5,5,,103178022,60021,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
157,625209,4,7,,103178022,60021,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
158,625210,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
159,625211,1,6,,103178022,60021,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
160,625212,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
161,625213,4,7,,103178022,60021,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
162,625214,1,9,,103178022,60021,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
163,625215,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
164,625216,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
165,625217,4,7,,103178022,60021,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
166,625218,4,7,,103178022,60021,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
167,625219,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
168,625220,4,7,,103178022,60021,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
169,625221,4,7,,103178022,60021,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
170,625222,4,7,,103178022,60021,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
171,625223,4,7,,103178022,60021,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
172,625224,3,4,,103178022,60021,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
173,625225,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
174,625226,4,7,,103178022,60021,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
175,625227,4,7,,103178022,60021,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
176,625228,4,7,,103178022,60021,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
177,625229,5,5,,103178022,60021,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
178,625230,1,6,,103178022,60021,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
179,625231,4,7,,103178022,60021,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
180,625232,1,9,,103178022,60021,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
181,625233,4,7,,103178022,60021,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
182,625234,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
183,625235,4,7,,103178022,60021,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
184,625236,5,5,,103178022,60021,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
185,625237,4,7,,103178022,60021,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
186,625238,4,7,,103178022,60021,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
187,625239,4,7,,103178022,60021,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
188,625240,1,9,,103178022,60021,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
189,625241,4,7,,103178022,60021,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
190,625242,4,7,,103178022,60021,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
191,625243,5,5,,103178022,60021,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
192,625244,5,5,,103178022,60021,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
193,625245,5,5,,103178022,60021,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
194,625246,1,9,,103178022,60021,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
195,625247,5,5,,103178022,60021,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
196,625248,5,5,,103178022,60021,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
197,625249,5,5,,103178022,60021,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
198,625250,5,5,,103178022,60021,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
199,625251,5,5,,103178022,60021,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
200,625252,4,7,,103178022,60021,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
201,625253,4,7,,103178022,60021,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
202,625254,4,7,,103178022,60021,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
203,625255,4,7,,103178022,60021,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
204,625256,4,7,,103178022,60021,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
205,625257,4,7,,103178022,60021,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
206,625258,4,7,,103178022,60021,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
207,625259,4,7,,103178022,60021,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
208,625260,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
209,625261,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
210,625262,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
211,625263,4,7,,103178022,60021,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
212,625264,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
213,625265,1,6,,103178022,60021,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
214,625266,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
215,625267,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
216,625268,4,2,,103178022,60021,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
217,625268,4,2,,103178022,60021,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
218,625268,4,2,,103178022,60021,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
219,625268,4,2,,103178022,60021,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
220,625269,4,7,,103178022,60021,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
221,625270,4,7,,103178022,60021,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
222,625271,5,5,,103178022,60021,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
223,625272,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
224,625273,4,6,,103178022,60021,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
225,625274,1,6,,103178022,60021,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
226,625275,3,4,,103178022,60021,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
227,625295,1,3,,103178022,60021,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data,Other,22194678.0,
228,651631,4,1,,144206857,60021,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
229,651632,4,1,,144206857,60021,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
230,651633,4,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
231,651634,4,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
232,652048,1,2,,144206857,60021,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
233,652051,1,1,,144206857,60021,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
234,686978,1,1,,144206857,60021,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
235,686979,1,1,,144206857,60021,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
236,720516,2,1,,144206857,60021,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
237,720532,1,1,,144206857,60021,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
238,720533,1,1,,144206857,60021,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
239,720552,2,1,,144206857,60021,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
240,720634,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
241,720635,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
242,720637,2,1,,144206857,60021,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
243,720674,2,2,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
244,720675,2,2,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
245,720678,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
246,720679,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
247,720680,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
248,720681,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
249,720682,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
250,720683,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
251,720684,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
252,720685,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
253,720686,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
254,720687,2,2,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
255,720691,4,1,,144206857,60021,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
256,720692,3,1,,144206857,60021,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
257,720693,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
258,720719,2,1,,144206857,60021,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
259,720725,2,1,,144206857,60021,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
260,743012,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
261,743014,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
262,743015,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
263,743033,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
264,743035,2,1,,144206857,60021,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
265,743036,2,1,,144206857,60021,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
266,743040,3,1,,144206857,60021,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
267,743041,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
268,743042,3,1,,144206857,60021,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
269,743053,2,1,,144206857,60021,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
270,743054,2,1,,144206857,60021,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
271,743063,2,1,,144206857,60021,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
272,743064,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
273,743065,3,1,,144206857,60021,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
274,743066,3,1,,144206857,60021,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
275,743067,2,1,,144206857,60021,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
276,743069,2,1,,144206857,60021,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
277,743074,2,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
278,743075,2,1,,144206857,60021,Inactive,348019627.0,2099.0,9.5205,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
279,743077,2,1,,144206857,60021,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
280,743078,2,1,,144206857,60021,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
281,743079,3,1,,144206857,60021,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
282,743080,3,1,,144206857,60021,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
283,743081,3,1,,144206857,60021,Inconclusive,,,37.578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
284,743083,3,1,,144206857,60021,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
285,743084,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
286,743085,3,1,,144206857,60021,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
287,743086,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
288,743091,2,1,,144206857,60021,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
289,743094,3,1,,144206857,60021,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
290,743122,2,1,,144206857,60021,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
291,743139,2,1,,144206857,60021,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
292,743140,2,1,,144206857,60021,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
293,743191,3,1,,144206857,60021,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
294,743194,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
295,743199,2,1,,144206857,60021,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
296,743202,4,1,,144206857,60021,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
297,743203,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
298,743209,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
299,743210,4,1,,144206857,60021,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
300,743211,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
301,743212,3,1,,144206857,60021,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
302,743213,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
303,743215,3,1,,144206857,60021,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
304,743217,3,1,,144206857,60021,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
305,743218,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
306,743219,3,1,,144206857,60021,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
307,743220,3,1,,144206857,60021,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
308,743221,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
309,743222,3,1,,144206857,60021,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
310,743223,3,1,,144206857,60021,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
311,743224,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
312,743225,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
313,743226,2,1,,144206857,60021,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
314,743227,2,1,,144206857,60021,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
315,743228,3,1,,144206857,60021,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
316,743239,2,1,,144206857,60021,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
317,743240,2,1,,144206857,60021,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
318,743241,2,1,,144206857,60021,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
319,743242,2,1,,144206857,60021,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
320,743244,1,1,,144206857,60021,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
321,931098,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S030408,Other,,
322,932847,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S030408,Other,,
323,932848,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S030408,Other,,
324,932849,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S030408,Other,,
325,932850,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S030408,Other,,
326,932851,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S030408,Other,,
327,932852,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S030408,Other,,
328,932853,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S030408",Other,,
329,932854,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S030408,Other,,
330,933115,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S030408,Other,,
331,933116,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S030408,Other,,
332,933117,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S030408,Other,,
333,933118,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S030408,Other,,
334,933119,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S030408,Other,,
335,933120,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S030408,Other,,
336,933121,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S030408,Other,,
337,933122,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S030408,Other,,
338,933123,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S030408,Other,,
339,933124,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S030408,Other,,
340,933125,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S030408",Other,,
341,933126,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S030408,Other,,
342,933127,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S030408,Other,,
343,933128,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S030408,Other,,
344,933129,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S030408,Other,,
345,933130,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S030408,Other,,
346,933131,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S030408,Other,,
347,933132,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S030408,Other,,
348,933482,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S030408,Other,,
349,933483,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S030408,Other,,
350,933484,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S030408,Other,,
351,933485,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S030408,Other,,
352,933486,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S030408,Other,,
353,933487,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S030408,Other,,
354,933488,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S030408,Other,,
355,933489,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S030408,Other,,
356,933490,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S030408,Other,,
357,933491,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S030408,Other,,
358,933492,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S030408,Other,,
359,961503,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S030408,Other,,
360,961504,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S030408,Other,,
361,961505,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S030408,Other,,
362,961506,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S030408,Other,,
363,961507,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S030408,Other,,
364,961508,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S030408,Other,,
365,961509,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S030408,Other,,
366,961510,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S030408,Other,,
367,961511,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S030408,Other,,
368,961512,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S030408,Other,,
369,961513,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S030408,Other,,
370,961514,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S030408,Other,,
371,961515,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S030408,Other,,
372,961516,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S030408,Other,,
373,961517,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S030408,Other,,
374,961518,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S030408,Other,,
375,961519,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S030408,Other,,
376,961520,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S030408,Other,,
377,961521,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S030408,Other,,
378,965381,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S030408,Other,,
379,976573,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S030408,Other,,
380,976574,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S030408,Other,,
381,976575,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S030408,Other,,
382,976576,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S030408,Other,,
383,976577,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S030408,Other,,
384,976578,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S030408,Other,,
385,976579,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S030408,Other,,
386,976580,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S030408,Other,,
387,976581,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S030408,Other,,
388,976582,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S030408,Other,,
389,976583,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S030408,Other,,
390,976584,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S030408,Other,,
391,976585,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S030408,Other,,
392,976586,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S030408,Other,,
393,976587,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S030408,Other,,
394,976588,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S030408,Other,,
395,976589,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S030408,Other,,
396,976590,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S030408,Other,,
397,1032771,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S030408,Other,,
398,1032772,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S030408",Other,,
399,1032773,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S030408",Other,,
400,1032774,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S030408",Other,,
401,1032775,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S030408",Other,,
402,1032776,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S030408",Other,,
403,1032777,1,3,,103178022,60021,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S030408,Other,,
404,1032778,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S030408",Other,,
405,1032779,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S030408",Other,,
406,1032780,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S030408",Other,,
407,1032781,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S030408",Other,,
408,1032782,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S030408",Other,,
409,1032783,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S030408",Other,,
410,1032784,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S030408",Other,,
411,1032785,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S030408",Other,,
412,1032786,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S030408",Other,,
413,1032787,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S030408",Other,,
414,1032788,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S030408",Other,,
415,1032789,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S030408",Other,,
416,1032790,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S030408",Other,,
417,1032791,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S030408",Other,,
418,1032792,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S030408",Other,,
419,1033375,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S030408",Other,,
420,1033376,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S030408",Other,,
421,1033377,1,3,,103178022,60021,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S030408",Other,,
422,1079931,1,1,,103178022,60021,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
423,1079932,1,1,,103178022,60021,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
424,1079933,1,1,,103178022,60021,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
425,1079934,1,1,,103178022,60021,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
426,1079935,1,1,,103178022,60021,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
427,1079936,1,1,,103178022,60021,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
428,1079937,1,1,,103178022,60021,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
429,1079938,1,1,,103178022,60021,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
430,1079939,1,1,,103178022,60021,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
431,1079940,1,1,,103178022,60021,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
432,1079941,1,1,,103178022,60021,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
433,1079942,1,1,,103178022,60021,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
434,1079943,1,1,,103178022,60021,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
435,1079944,1,1,,103178022,60021,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
436,1079945,1,1,,103178022,60021,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
437,1079946,1,1,,103178022,60021,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
438,1079947,1,1,,103178022,60021,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
439,1079948,1,1,,103178022,60021,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
440,1079949,1,1,,103178022,60021,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
441,1117298,1,2,,144206857,60021,Inactive,,,3.9811,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
442,1117304,1,2,,144206857,60021,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
443,1117305,1,2,,144206857,60021,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
444,1117310,1,1,,144206857,60021,Inactive,,,3.98107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
445,1117312,1,1,,144206857,60021,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
446,1117314,1,1,,144206857,60021,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
447,1117326,1,1,,144206857,60021,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
448,1117329,1,1,,144206857,60021,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
449,1117336,1,1,,144206857,60021,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
450,1117340,1,1,,144206857,60021,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
451,1117341,1,1,,144206857,60021,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
452,1117342,1,1,,144206857,60021,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
453,1117343,1,1,,144206857,60021,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
454,1117346,1,1,,144206857,60021,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
455,1159509,1,1,,144206857,60021,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
456,1159515,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
457,1159516,1,1,,144206857,60021,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
458,1159517,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
459,1159518,1,1,,144206857,60021,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
460,1159519,1,1,,144206857,60021,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
461,1159520,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
462,1159521,1,1,,144206857,60021,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
463,1159523,1,1,,144206857,60021,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
464,1159525,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
465,1159526,1,1,,144206857,60021,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
466,1159527,1,1,,144206857,60021,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
467,1159528,1,1,,144206857,60021,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
468,1159529,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
469,1159531,1,1,,144206857,60021,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
470,1159551,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
471,1159552,1,1,,144206857,60021,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
472,1159553,2,1,,144206857,60021,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
473,1159555,1,1,,144206857,60021,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
474,1159614,1,2,,144206857,60021,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
475,1224834,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
476,1224835,1,1,,144206857,60021,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
477,1224836,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
478,1224837,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
479,1224838,1,1,,144206857,60021,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
480,1224839,1,1,,144206857,60021,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
481,1224840,3,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
482,1224841,3,1,,144206857,60021,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
483,1224842,3,1,,144206857,60021,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
484,1224843,1,1,,144206857,60021,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
485,1224844,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
486,1224845,1,1,,144206857,60021,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
487,1224846,1,1,,144206857,60021,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
488,1224847,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
489,1224848,3,1,,144206857,60021,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
490,1224849,3,1,,144206857,60021,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
491,1224857,2,1,,144206857,60021,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
492,1224859,2,1,,144206857,60021,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
493,1224867,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
494,1224868,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
495,1224869,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
496,1224870,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
497,1224871,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
498,1224872,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
499,1224873,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
500,1224874,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
501,1224875,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
502,1224876,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
503,1224877,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
504,1224878,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
505,1224879,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
506,1224880,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
507,1224881,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
508,1224882,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
509,1224883,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
510,1224884,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
511,1224885,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
512,1224886,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
513,1224887,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
514,1224888,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
515,1224889,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
516,1224890,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
517,1224892,1,1,,144206857,60021,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
518,1224893,1,1,,144206857,60021,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
519,1224894,1,1,,144206857,60021,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
520,1224895,1,1,,144206857,60021,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
521,1224896,1,1,,144206857,60021,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
522,1224923,1,1,,103178022,60021,Active,,,,,Summary of drugs withdrawn.,Other,,
523,1259241,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
524,1259242,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
525,1259243,1,1,,144206857,60021,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
526,1259244,1,1,,144206857,60021,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
527,1259247,1,1,,144206857,60021,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
528,1259248,1,1,,144206857,60021,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
529,1259344,1,1,,144206857,60021,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
530,1259364,1,1,,144206857,60021,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
531,1259365,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
532,1259366,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
533,1259367,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
534,1259368,1,1,,144206857,60021,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
535,1259369,1,1,,144206857,60021,Inactive,109731339.0,2737.0,2.371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
536,1259377,1,1,,144206857,60021,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
537,1259378,1,1,,144206857,60021,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
538,1259379,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
539,1259380,1,1,,144206857,60021,Inconclusive,,,2.1132,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
540,1259381,1,1,,144206857,60021,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
541,1259382,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
542,1259383,1,1,,144206857,60021,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
543,1259384,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
544,1259385,1,1,,144206857,60021,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
545,1259386,1,1,,144206857,60021,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
546,1259387,1,1,,144206857,60021,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
547,1259388,1,1,,144206857,60021,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
548,1259390,1,1,,144206857,60021,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
549,1259391,1,1,,144206857,60021,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
550,1259392,1,1,,144206857,60021,Inconclusive,109731339.0,2737.0,2.51151,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
551,1259393,1,1,,144206857,60021,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
552,1259394,1,1,,144206857,60021,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
553,1259395,1,1,,144206857,60021,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
554,1259396,1,1,,144206857,60021,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
555,1259400,1,1,,124894572,60021,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
556,1259401,1,1,,144206857,60021,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
557,1259402,1,1,,144206857,60021,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
558,1259403,1,1,,144206857,60021,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
559,1259404,1,1,,144206857,60021,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
560,1259407,1,1,,363904253,60021,Active,,,,,CCRIS mutagenicity studies,Other,,
